RESUMEN
The molecular maker system - TRAP was applied to develop a novel and more accurate method to identify the variety and establish the evolutionary relationship of different categories of Dendranthema morifolium. A software - GENESIS 2.4 was used to conduct the cluster analysis and genetic dendrogram establishment. The results showed that 202 different fragments were amplified with 6 pair primers using the TRAP marker system. The polymorphic fragments number is 45, which takes up to 22.3%. The cluster analysis showed that 4 materials used in this study can be classified into 2 main groups and 3 subgroups. The genetic identity is 0.0767 and the average genetic distance is 0.9236 among the four materials. A new tool using the TRAP marker system is more accurate and can be used to identify different categories of Dendranthema morifolium at molecular level.
Asunto(s)
Chrysanthemum/genética , Marcadores Genéticos , Técnicas Genéticas , Evolución Biológica , China , Análisis por Conglomerados , Medicamentos Herbarios Chinos , Etiquetas de Secuencia Expresada , Genética de Población , Filogenia , Reacción en Cadena de la Polimerasa/métodos , Polimorfismo Genético , Programas InformáticosRESUMEN
OBJECTIVES: To compare the efficacy and tolerability of dihydroartemisinin-piperaquine (DHA-PQP) with that of a 3-day regimen of mefloquine and artesunate (MAS3) for the treatment of uncomplicated falciparum malaria in Cambodia. METHOD: Randomized open-label non-inferiority study over 64 days. RESULTS: Four hundred and sixty-four patients were included in the study. The polymerase chain reaction genotyping-adjusted cure rates on day 63 were 97.5% (95% confidence interval, CI, 93.8-99.3) for DHA-PQP and 97.5% (95% CI, 93.8-99.3) for MAS3, P = 1. There were no serious adverse events, but significantly more episodes of vomiting (P = 0.03), dizziness (P = 0.002), palpitations (P = 0.04), and sleep disorders (P = 0.03) reported in the MAS3 treatment group, consistent with the side-effect profile of mefloquine. CONCLUSIONS: DHA-PQP was as efficacious as MAS3, but much better tolerated, making it more appropriate for use in a routine programme setting. This highly efficacious, safe and more affordable fixed-dose combination could become the treatment of choice for Plasmodium falciparum malaria in Cambodia.